Beaumont Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Beaumont Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Sell	412 -98	-19%	-$43.4K	0.01%	367
2026 Q1	$228K	Buy	510 +24	+5%	+$11.2K	0.02%	337
2025 Q4	$220K	Buy	+486	New	+$209K	0.01%	349
2025 Q3	–	Sell	-496	Closed	-$221K	–	404
2025 Q2	$221K	Buy	496 +5	+1%	+$2.3K	0.02%	352
2025 Q1	$238K	Buy	+491	New	+$229K	0.02%	327
2024 Q4	–	Sell	-461	Closed	-$214K	–	380
2024 Q3	$214K	Sell	461 -7	-1%	-$3.36K	0.02%	332
2024 Q2	$219K	Sell	468 -23	-5%	-$9.98K	0.02%	331
2024 Q1	$205K	Sell	491 -18	-4%	-$7.61K	0.02%	349
2023 Q4	$207K	Buy	+509	New	+$188K	0.02%	325

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Beaumont Financial Advisors's VRTX Position: Q2 2026 in Review

Beaumont Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2026, selling an estimated $43.4K and leaving 412 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #367.

Beaumont Financial Advisors first reported a position in VRTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $238K in Q1 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Beaumont Financial Advisors held 412 shares of Vertex Pharmaceuticals worth $205K as of Q2 2026.
Beaumont Financial Advisors sold 98 Vertex Pharmaceuticals shares in Q2 2026, an estimated $43.4K.
Vertex Pharmaceuticals made up 0.01% of Beaumont Financial Advisors's portfolio in Q2 2026, its #367 holding.
Beaumont Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Beaumont Financial Advisors's Vertex Pharmaceuticals position peaked at $238K in Q1 2025.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Beaumont Financial Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.